A Study Comparing Irinotecan and Cisplatin (IP) With Etoposide and Cisplatin (EP) Following EP/TRT for LD-SCLC
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00144989 |
Recruitment Status :
Completed
First Posted : September 5, 2005
Last Update Posted : September 22, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Small-Cell-Lung Cancer | Drug: Etoposide and cisplatin after chemoradiotherapy Drug: Irinotecan and cisplatin after chemoradiotherapy | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 281 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase III Study Comparing Etoposide and Cisplatin (EP) With Irinotecan and Cisplatin (IP) Following EP Plus Concurrent Accelerated Hyperfractionated Thoracic Irradiation (EP/TRT) for Limited-Stage Small-Cell Lung Cancer : JCOG0202-MF |
Study Start Date : | September 2002 |
Actual Primary Completion Date : | September 2011 |
Actual Study Completion Date : | September 2011 |
Arm | Intervention/treatment |
---|---|
Active Comparator: 1
Etoposide and cisplatin after chemoradiotherapy
|
Drug: Etoposide and cisplatin after chemoradiotherapy
Etoposide and cisplatin after chemoradiotherapy |
Experimental: 2
Irinotecan and cisplatin after chemoradiotherapy
|
Drug: Irinotecan and cisplatin after chemoradiotherapy
Irinotecan and cisplatin after chemoradiotherapy |
- overall survival [ Time Frame: during the study conduct ]
- adverse events of induction chemoradiotherapy [ Time Frame: during the study conduct ]
- chemotherapy after chemoradiotherapy [ Time Frame: during the study conduct ]
- late radiation morbidity [ Time Frame: during the study conduct ]
- serious adverse event [ Time Frame: during the study conduct ]
- progression-free survival [ Time Frame: during the study conduct ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- cytologically, histologically proven small-cell lung cancer
- limited disease
- age 20-70 years old
- performance status of 0-1
- measurable disease
- no prior treatment for small-cell lung cancer
- no history of chemotherapy
- adequate organ functions
- written informed consent
Exclusion Criteria:
- pericardial effusion
- active concomitant malignancy
- pregnant or lactating women
- interstitial pneumonia/active lung fibrosis on chest x-ray, watery diarrhea, intestinal obstruction or paralysis, uncontrolled heart disease or a history of myocardial infarction within the previous 6 months, uncontrolled diabetes mellitus, active infection, psychological disease deemed unacceptable for inclusion to the study, long-term steroid treatment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00144989
Study Chair: | Yutaka Nishiwaki, MD | National Cancer Center Hospital East |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Haruhiko Fukuda, JCOG Data Center, Japan Clinical Oncology Group |
ClinicalTrials.gov Identifier: | NCT00144989 |
Other Study ID Numbers: |
JCOG0202-MF C000000095 |
First Posted: | September 5, 2005 Key Record Dates |
Last Update Posted: | September 22, 2016 |
Last Verified: | September 2016 |
Small-cell lung cancer Limited-Stage Small-Cell Lung Cancer Combined modality therapy chemotherapy |
radiotherapy Irinotecan Cisplatin |
Lung Neoplasms Small Cell Lung Carcinoma Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms |
Cisplatin Irinotecan Etoposide Antineoplastic Agents Topoisomerase I Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents, Phytogenic Topoisomerase II Inhibitors |